Category Archives: pricing

Is Gilead’s $1000 Pill Worth It?

The Department of Veterans Affairs and other California panels’ solution to the new and extremely costly hepatitis (Hep) C drugs (Sovaldi and Olysio) is to reserve them for the patients with advanced liver diseases, including those awaiting transplants. What should the patients of “milder” cases do then? Twiddle their thumbs and wait for drugs in […]
Also posted in Regulatory | Tagged , , , , | 2 Comments

The US Biotech Drug Pricing Challenge

by Tom Norton In the midst of the hue and cry last week over the public release of individual Medicare payments to physicians, I was surprised to read that one of Medicare’s most costly medical services is — ophthalmology.  According to the New York Times: “One of the most heavily reimbursed procedures — costing a […]
Also posted in Biotech, Corporate Responsibility, Guest Blog, healthcare, Market Access, Strategy | Tagged , , , , , , , , | 1 Comment

Medicare Payment Data Raises Questions About Drug Costs

Even though the just-released Medicare data on payments to individual doctors doesn’t provide specifics on prescription drug outlays, it opens the door to sharp scrutiny of Medicare reimbursement for medicines delivered in physician offices. The Centers for Medicare and Medicaid Services (CMS) has released data on payments to some 880,000 health care providers who collectively […]
Also posted in healthcare, Legal, Regulatory | Tagged , , , | Leave a comment

Pricing and Reimbursement in Europe: Where Does Innovation Fit?

By Leela Barham. It was recently said, in reference to the UK’s Value-Based Assessment(VBA) program, that innovation had not been “tried and tested in the pricing context”, which explains the loss of the “innovation” criteria from the proposals formerly known as Value-Based Pricing (VBP). This prompted me to think about just how has innovation been […]
Also posted in Europe, Global, Guest Blog, R&D | Tagged , , , , , | Leave a comment

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Also posted in Biotech, healthcare, leadership, Market Access, R&D, Sales, Strategy | Tagged , , , , , , , , , | 1 Comment
  • Categories

  • Meta